Evidence map›Paper›PMID 26401779›Full record

Trial reportJournal of Alzheimer's disease : JAD2015

Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.

Carey E Gleason, Barbara L Fischer, N Maritza Dowling, Kenneth D R Setchell, Craig S Atwood, Cynthia M Carlsson, Sanjay Asthana

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00205179 (Alzheimer's Disease), which is not on this map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00205179 phase2completednot on this map

Alzheimer's Disease: Potential Benefit of Isoflavones

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2005 to 2009Enrolled72ConditionsAlzheimer's DiseaseArmsNovasoy, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Dietary Flavonoids and Human Cognition: A Meta-Analysis.Molecular nutrition & food research · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Carey E GleasonDivision of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Barbara L FischerDivision of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
N Maritza DowlingWisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Kenneth D R SetchellDivision of Pathology and Laboratory Medicine, Department of Pediatrics University of Cincinnati, Cincinnati, OH, USA.
Craig S AtwoodDivision of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Cynthia M CarlssonDivision of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Sanjay AsthanaDivision of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA.
Geriatric Research Education and Clinical Center · USUniversity of Wisconsin–Madison · USUniversity of Cincinnati · USWilliam S. Middleton Memorial Veterans Hospital · USWisconsin Division of Public Health · US

Funding

Statistical Data Enclave CoreP30AG017266 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Michal Engelman · 1999 to 2026
$17.0M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHAPPELL, RICHARD J · 2009 to 2018
$16.2M
Alzheimer's Disease: Potential Benefit of IsoflavonesK23AG024302 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI GLEASON, CAREY E · 2004 to 2008
$661k
NIA NIH HHS K23 AG024302NIA NIH HHS P30 AG017266NIA NIH HHS P50 AG033514
6 · The paper itself

Abstract

backgroundIn a previous trial, treatment with soy isoflavones was associated with improved nonverbal memory, construction abilities, verbal fluency, and speeded dexterity compared to treatment with placebo in cognitively healthy older adults.

objectiveThe current trial aimed to examine the potential cognitive benefits of soy isoflavones in patients with Alzheimer's disease.

methodsSixty-five men and women over the age of 60 were treated with 100 mg/day soy isoflavones, or matching placebo capsules for six months. APOE genotype was determined for all participants. Cognitive outcomes and plasma isoflavone levels were measured at baseline, and at two additional time points: three and six months after baseline.

resultsOf the sixty-five participants enrolled, thirty-four (52.3% ) were women, and 31 (47.7% ) were APOEɛ4 positive. Average age was 76.3 (SD = 7.2) years. Fifty-nine (90.8% ) subjects completed all study visits. Plasma isoflavone levels increased in subjects treated with soy isoflavones compared to baseline and to placebo, although intersubject variability in plasma levels was large. No significant differences in treatment effects for cognition emerged between treatment groups or genders. Exploratory analyses of associations between changes in cognition and plasma isoflavone levels revealed an association between equol levels, and speeded dexterity and verbal fluency.

conclusionsSix months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease. However, our results suggest the need to examine the role of isoflavone metabolism, i.e., the ability to effectively metabolize soy isoflavones by converting daidzen to equol when attempting to fully clarify the cognitive effects of isoflavones.

Indexed as

Dietary SupplementsAffectAgedAlzheimer DiseaseCognitionDouble-Blind MethodFemaleHumansIsoflavonesMaleMotor SkillsNootropic AgentsPatient ComplianceSex FactorsSoybean ProteinsTreatment OutcomeIsoflavonesNootropic AgentsSoybean ProteinsAlzheimer’s diseaseclinical trialcognitiondaidzeinequolgenisteinphytoestrogenssoy isoflavones

Identifiers

PMID26401779
PMCPMC4657545
OpenAlexW2224267711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.